These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 11862501

  • 1. Is there a role for melatonin in supportive care?
    Lissoni P.
    Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
    [Abstract] [Full Text] [Related]

  • 2. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
    Lissoni P.
    Pathol Biol (Paris); 2007 Mar; 55(3-4):201-4. PubMed ID: 17446010
    [Abstract] [Full Text] [Related]

  • 3. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
    Lissoni P, Malugani F, Brivio F, Piazza A, Vintimilla C, Giani L, Tancini G.
    Neuro Endocrinol Lett; 2003 Mar; 24(3-4):259-62. PubMed ID: 14523367
    [Abstract] [Full Text] [Related]

  • 4. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
    Lissoni P, Rovelli F, Frassineti A, Fumagalli L, Malysheva O, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2000 Mar; 21(4):319-323. PubMed ID: 11455367
    [Abstract] [Full Text] [Related]

  • 5. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F.
    Anticancer Res; 2008 Mar; 28(2B):1377-81. PubMed ID: 18505083
    [Abstract] [Full Text] [Related]

  • 6. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
    Lissoni P.
    Pathol Biol (Paris); 2007 Mar; 55(3-4):198-200. PubMed ID: 17451889
    [Abstract] [Full Text] [Related]

  • 7. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ.
    J Biol Regul Homeost Agents; 1997 Mar; 11(3):119-22. PubMed ID: 9498162
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000 Mar; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 9. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [Abstract] [Full Text] [Related]

  • 10. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
    Brackowski R, Zubelewicz B, Romanowski W, Lissoni P, Barni S, Tancini G, Maestroni GJ.
    J Biol Regul Homeost Agents; 1994 Aug; 8(3):77-80. PubMed ID: 7754792
    [Abstract] [Full Text] [Related]

  • 11. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P, Rovelli F, Meregalli S, Fumagalli L, Musco F, Brivio F, Brivio O, Esposti G.
    J Biol Regul Homeost Agents; 1997 Aug; 11(4):157-9. PubMed ID: 9582617
    [Abstract] [Full Text] [Related]

  • 12. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
    Lissoni P, Barni S, Tancini G, Brivio F, Tisi E, Zubelewicz B, Braczkowski R.
    J Biol Regul Homeost Agents; 1994 Aug; 8(4):126-9. PubMed ID: 7660855
    [Abstract] [Full Text] [Related]

  • 13. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
    Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F.
    Nat Immun; 1998 Aug; 16(1):27-33. PubMed ID: 9789122
    [Abstract] [Full Text] [Related]

  • 14. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P.
    Anticancer Res; 2003 Aug; 23(2C):1951-4. PubMed ID: 12820485
    [Abstract] [Full Text] [Related]

  • 15. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995 Aug; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 16. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
    Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G.
    In Vivo; 2008 Aug; 22(3):397-400. PubMed ID: 18610754
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Aug; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 18. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study.
    Yan JJ, Shen F, Wang K, Wu MC.
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):183-6. PubMed ID: 14607735
    [Abstract] [Full Text] [Related]

  • 19. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients.
    Lissoni P, Malugani F, Bukovec R, Bordin V, Perego M, Mengo S, Ardizzoia A, Tancini G.
    Neuro Endocrinol Lett; 2003 May; 24(1-2):83-5. PubMed ID: 12743539
    [Abstract] [Full Text] [Related]

  • 20. Melatonin as biological response modifier in cancer patients.
    Neri B, de Leonardis V, Gemelli MT, di Loro F, Mottola A, Ponchietti R, Raugei A, Cini G.
    Anticancer Res; 1998 May; 18(2B):1329-32. PubMed ID: 9615811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.